End Delay of Drug Price Transparency Rule, Employer Group Urges

An employer group wants the Biden administration to move ahead with requirements making detailed drug price information public as momentum grows behind the issue.

A public policy think tank is also suing to hurry the process, while a House panel is holding a hearing Tuesday on making prices easier to find and track.

“All the employer groups are in favor of transparency,” James Gelfand, president of the ERISA Industry Committee, said in an interview, but the Biden administration indefinitely delayed implementation of the drug price provisions of the Trump administration’s 2020 transparency in coverage rule when the Pharmaceutical Care Management ...